SLC5A2 and diabetes mellitus: The 2022 update of the Kidney Disease Improving Global Outcomes (KDIGO) guidelines for diabetes management in chronic kidney disease recommends the initiation of treatment with an SGLT-2-inhibitor in people with DM type 2 and CKD.